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Hemochromatosis is caused by mutations in HFE,
a protein that competes with transferrin (TF) for bind-
ing to transferrin receptor 1 (TFR1). We developed
mutant mouse strains to gain insight into the role of
the Hfe/Tfr1 complex in regulating iron homeostasis.
We introduced mutations into a ubiquitously ex-
pressed Tfr1 transgene or the endogenous Tfr1 locus
to promote or prevent the Hfe/Tfr1 interaction. Under
conditions favoring a constitutive Hfe/Tfr1 interac-
tion, mice developed iron overload attributable to
inappropriately low expression of the hormone hepci-
din. In contrast, mice carrying a mutation that inter-
feres with the Hfe/Tfr1 interaction developed iron de-
ficiencyassociatedwith inappropriatelyhighhepcidin
expression. High-level expression of a liver-specific
Hfe transgene in Hfe/ mice was also associated
with increased hepcidin production and iron defi-
ciency. Together, these models suggest that Hfe in-
duces hepcidin expression when it is not in complex
with Tfr1.
INTRODUCTION
Hemochromatosis is a prevalent iron overload disease caused
by a chronic increase in intestinal absorption of dietary iron.
Most patients are homozygous for a C282Y mutation in HFE,
a gene encoding an atypical major histocompatibility class I-
like molecule. Mice carrying homozygous mutations disrupting
the Hfe gene (Hfe/ and HfeC282Y/C282Y) have phenotypes that
are very similar to human hemochromatosis (Ajioka et al.,
2002; Levy et al., 1999b).
Although HFE is inferred to play a role in the regulation of
intestinal iron absorption, its molecular function remains uncer-
tain. HFE forms protein complexes with transferrin receptor 1
(TFR1) and its liver-specific homolog, transferrin receptor 2
(TFR2) (Feder et al., 1998; Goswami and Andrews, 2006; Parkkila
et al., 1997; Waheed et al., 1999). Diferric transferrin (Fe-TF) candisplace HFE from TFR1, because TF and HFE compete for over-
lapping binding sites on TFR1 (Bennett et al., 2000; Giannetti and
Bjorkman, 2004; Lebron et al., 1998; Lebron and Bjorkman,
1999). Fe-TF also induces an increase in TFR2 protein stability
(Johnson and Enns, 2004; Robb and Wessling-Resnick, 2004).
Initially, prevailing models postulated that HFE alters cellular
uptake of iron through the TF cycle, thus programming intestinal
absorptive cells to increase iron uptake. However, mice with du-
odenum-specific ablation of Hfe have been reported to have no
disruption of iron metabolism (Vujic Spasic et al., 2007). Expres-
sion of the iron regulatory hormone hepcidin has been shown to
be inappropriately low in patients with HFE hemochromatosis
and in Hfe/ mice (Bridle et al., 2003; Muckenthaler et al.,
2003; Nicolas et al., 2003). Forced expression of a hepcidin
transgene corrects the hemochromatosis phenotype in Hfe/
mice, consistent with the interpretation that the primary role of
Hfe is to control hepcidin expression (Nicolas et al., 2003). Hep-
cidin is produced by hepatocytes, which express more HFE than
other cell types in the liver (Zhang et al., 2004). Furthermore, HFE
hemochromatosis patients who have undergone orthotopic liver
transplantation do not demonstrate reaccumulation of excess
liver iron or markedly increased serum iron posttransplantation
(Bralet et al., 2004). These observations refocused attention on
HFE in hepatocytes, suggesting that the liver is the physiologi-
cally important site of the HFE/TFR1 and HFE/TFR2 interactions.
Hepcidin modulates iron homeostasis by binding to the iron
exporter ferroportin at the cell surface, triggering ferroportin in-
ternalization and degradation (Nemeth et al., 2004b). Hepcidin-
mediated inactivation of ferroportin on intestinal epithelial cells
and macrophages apparently leads to decreased dietary iron
absorption and accumulation of iron within the macrophage
iron-recycling compartment (Donovan et al., 2005). In HFE he-
mochromatosis, production of hepcidin is inappropriately low
for overall body iron status. Consequently, ferroportin activity
is not attenuated, leading to increased iron absorption, in-
creased return of macrophage iron to the circulation, and depo-
sition of surplus iron in parenchymal cells of target organs.
Hepcidin production is modulated in response to several
physiological conditions. It increases in iron overload and de-
creases in iron deficiency (Pigeon et al., 2001; Weinstein et al.,
2002). The occupancy of serum TF with iron has long beenCell Metabolism 7, 205–214, March 2008 ª2008 Elsevier Inc. 205
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Hfe Regulates Hepcidin ExpressionFigure 1. Surface Plasmon Resonance Analysis of Murine Hfe and Diferric Transferrin Binding to Mutant and Wild-Type Tfr1
(A) Experimentally observed responses are shown as black dots, with best fit binding curves (red lines) derived from a 1:1 interaction model superimposed. The
highest concentration protein injections are 12 mM (Hfe) and 3 mM (Fe-Tf), with subsequent injections related by a 3-fold dilution series. No Hfe binding to L622A
Tfr1 or Fe-Tf binding to R654A Tfr1 was observed at these concentrations. Given the concentration of proteins and the sensitivity of the surface plasmon res-
onance experiment, this suggests that the binding constants are weaker than 300 mM for Hfe and 30 mM for Fe-Tf. This is well above the physiological concen-
tration of transferrin in serum.
(B–D) Model of action for wild-type (B), R654A (C), and L622A (D) Tfr1 mutant proteins. The R654A Tfr1 mutation prevents Tf, but not Hfe, interaction with Tfr1. The
L622A Tfr1 mutation prevents Hfe, but not Tf, binding to Tfr1.thought to play a role in communicating information about body
iron stores (Cavill et al., 1975; Taylor and Gatenby, 1966). TF oc-
cupancy reflects the balance of iron entering the serum (from in-
testinal absorption, macrophage iron release, and hepatic iron
mobilization) and iron leaving the serum (primarily for utilization
in erythropoiesis). TFR1 has much higher affinity for Fe-TF than
for apo-TF (Aisen and Listowsky, 1980), suggesting that compe-
tition between HFE and TF for TFR1 binding might be modulated
by TF occupancy with iron. Furthermore, the fact that TFR2 ex-
pression is induced by Fe-TF suggests that the HFE/TFR2 inter-
action may also be altered by TF saturation. We hypothesized
that the purposes of the HFE/TFR1 and HFE/TFR2 interactions
might therefore be to regulate hepcidin expression in response
to body iron status. The HFE/TFR1 interaction is the subject of
this report.
We generated three mutant mouse strains to interrogate the
Hfe/Tfr1 interaction in vivo. First, we engineered a ubiquitously ex-
pressed Tfr1 transgene carrying a missense mutation (R654A)
that prevents Tf binding but does not affect the interaction of
Tfr1 and Hfe. These mice should have constitutive interaction of
Hfe with Tfr1. Second, we introduced a missense mutation
(L622A) into the endogenous Tfr1 locus that renders Tfr1 unable
to interact with Hfe but has no major effect on Tf binding. Mice ho-206 Cell Metabolism 7, 205–214, March 2008 ª2008 Elsevier Inc.mozygous for this allele should have an insignificant decrease in
the affinity of Tfr1 for Tf but no interaction of Hfe and Tfr1. Third,
we used the transthyretin (Ttr) promoter to specifically express
an Hfe transgene in hepatocytes of mice lacking endogenous
Hfe. The results obtained with all three strains support the conclu-
sion that Hfe dissociated from Tfr1, and not the Hfe/Tfr1 complex,
acts to induce hepcidin expression. We suggest that Tfr1 normally
acts to sequester Hfe and keep it inactive, and that competition
between Fe-Tf and Hfe for Tfr1 binding is a key component of
a liver-centered homeostatic regulatory mechanism. We specu-
late that Hfe released from Tfr1 interacts with Tfr2 to signal for
hepcidin production.
RESULTS
Generation of Tfr1Mutant Mice
To elucidate how the Hfe/Tfr1 interaction modulates iron homeo-
stasis in vivo, we took advantage of mutagenesis studies by
Bjorkman and colleagues characterizing interactions between
TFR1, HFE, and TF (Giannetti and Bjorkman, 2004; Giannetti
et al., 2003; West et al., 2001). The in vitro interaction profiles (Fig-
ure 1A) for the wild-type and mutant murine proteins as assessed
by surface plasmon resonance analysis were comparable to
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completely abrogates Fe-Tf binding and has no apparent effect
on the interaction with Hfe. Furthermore, the L622A mutation,
which removes an amino acid critical for a van der Waals interac-
tion between Hfe and Tfr1 but not for Tf binding, prevents Hfe-
Tfr1 binding but decreases the Tfr1 Fe-Tf interaction to a lesser
extent (approximately 20-fold). The altered affinity for Tf should
be inconsequential in vivo, where plasma Fe-Tf concentrations
still far exceed the Kd for binding. A model of action for wild-
type, R654A, and L622A Tfr1 is depicted in Figures 1B–1D. We
confirmed that the Fe uptake function of the mutant Tfr1 proteins
was consistent with the in vitro binding data by stably expressing
wild-type, R654A, or L622A Tfr1 in TRVb cells, which lack endog-
enous Tfr1 and Tfr2 (McGraw et al., 1987). When expressed at
similar levels, L622A Tfr1 mediated uptake of 55Fe-Tf at a rate
that was approximately half that of wild-type Tfr1. In contrast,
R654A Tfr1 had no apparent Fe-Tf uptake activity (see Figure S1
available online).
We previously observed that mice homozygous for a null Tfr1
allele die of severe anemia during embryogenesis (Levy et al.,
1999a), indicating that failure of the Tf cycle would have general
effects that could confound our analysis. Mice with haploinsuffi-
ciency for Tfr1 also have impaired erythropoiesis and slightly ab-
normal iron homeostasis (Levy et al., 1999a). For these reasons,
we developed a mutant strain that expresses an R654A allele of
Tfr1 constitutively from a heterologous locus (ROSA26), leaving
the endogenous Tfr1 locus intact (Figures S2A and S2B). We rea-
soned that the transgene product would not participate in the Tf
cycle but should form a complex with Hfe that would not be sub-
ject to competition from Tf.
We were able to use an alternative strategy to develop mice
carrying the other Tfr1 mutation. Since L622A does not prevent
Tf binding, we introduced a missense change resulting in that
substitution directly into the endogenous murine Tfr1 gene (Fig-
ures S2C and S2D). We will discuss analysis of these two mutant
mouse strains individually.
Analysis of Mice Expressing the Tfr1 R654A Transgene
Missense mutations in Tfr1 do not significantly alter its electro-
phoretic mobility. For this reason, we confirmed that animals ex-
pressing the Tfr1 R654A transgene produce more Tfr1 protein by
analyzing total liver extracts by western blot and comparing
them to wild-type and Hfe/ mice (Figure 2A). Tfr1 protein
was increased in animals carrying the transgene but was mark-
edly decreased in livers from Hfe/ mice, presumably because
their high total-body iron burden leads to destabilization of Tfr1
mRNA through its iron regulatory elements (reviewed in Eisen-
stein, 2000). However, the mutant allele does not encode 30
iron regulatory elements important for posttranscriptional regu-
lation of the mRNA, and, accordingly, Tfr1 was expressed at
higher levels in Hfe/ ROSA26Tfr1R654A/+ mice carrying one
copy of the transgene.
To confirm that expression of the Tfr1 R654A transgene does
not significantly impair the Tf cycle, we analyzed erythropoiesis
by automated complete blood counts. As shown in Table S1,
all erythroid parameters were normal, indicating that
ROSA26Tfr1R654A/Tfr1R654A mice had normal Tf cycle iron uptake
in the erythron, the tissue that is most dependent upon that
mechanism.We next evaluated iron homeostasis in
ROSA26Tfr1R654A/Tfr1R654A mice, comparing them with wild-type
and Hfe/ mice. We reasoned that expression of R654A Tfr1,
which is able to bind Hfe but not Tf, should promote a constitutive
Hfe/Tfr1 interaction (Figure 1C). If Hfe requires Tfr1 to induce
hepcidin expression, hepcidin mRNA should be increased in
mice expressing the Tfr1 R654A transgene; therefore, the ani-
mals might show evidence of iron deficiency. On the other
hand, if interaction with Tfr1 prevents Hfe from inducing hepcidin
expression, the phenotype of ROSA26Tfr1R654A/Tfr1R654A mice
should be similar to Hfe/ mice, which lack Hfe altogether.
We found thatROSA26Tfr1R654A/Tfr1R654A mice had significantly
increased occupancy of serum transferrin with iron (transferrin
saturation), similar to Hfe/ mice (Figure 2B). As shown in Table
S1, this was not due to decreased iron utilization for erythropoi-
esis. We can conclude, therefore, that more iron enters the se-
rum. Increased transferrin saturation is a hallmark feature of clin-
ical hemochromatosis. Mice carrying one allele of the Tfr1R654A
transgene on an Hfe/ background also had elevated transfer-
rin saturation. The absolute amount of serum transferrin varied
between animals and genotypes when evaluated by semiquan-
titative immunoblotting and measurement of total iron binding
capacity (data not shown). Compared to wild-type animals, it
was not significantly different in ROSA26Tfr1R654A/Tfr1R654A or
Hfe/ ROSA26Tfr1R654A/+ mice, but it was decreased in Hfe/
mice. We do not yet have an explanation for this observation.
Liver nonheme iron content reflects the total-body iron
endowment and is increased in hemochromatosis. RO-
SA26Tfr1R654A/Tfr1R654A liver nonheme ironcontent was significantly
increased as compared to wild-type controls, but less than ob-
served in Hfe/ mice (Figure 2C). Hfe/ ROSA26Tfr1R654A/+
mice had liver nonheme iron content intermediate between
ROSA26Tfr1R654A/Tfr1R654A and Hfe/ animals. The histological
pattern of iron deposition in ROSA26Tfr1R654A/Tfr1R654A mice was
predominantly periportal, similar to that observed in Hfe/ ani-
mals but to a lesser extent (Figures 2F–2H).
Patients with advanced hemochromatosis can have increased
nonheme iron deposition in the heart, which if left untreated can
lead to cardiomyopathy. Analyzed at 10 weeks of age, ourHfe/
mice had been previously shown to have a modest increase in
heart iron content (Miranda et al., 2003). Here, at 8 weeks of
age, we found no significant difference in heart nonheme iron
levels between wild-type and Hfe/ mice. Interestingly, how-
ever, ROSA26Tfr1R654A/Tfr1R654A mice did have significant heart
iron loading (Figure 2D). We do not yet understand why
ROSA26Tfr1R654A/Tfr1R654A mice accumulated more cardiac iron.
Increased Tf saturation and tissue iron overload in
ROSA26Tfr1R654A/Tfr1R654A mice suggest that an increased
propensity for Hfe to interact with Tfr1 mimics the Hfe/ pheno-
type. We predicted that, similar to Hfe/ mice, the
ROSA26Tfr1R654A/Tfr1R654A mice might express levels of hepcidin
inappropriately low for their overall iron status. As shown in
Figure 2E, iron overload in ROSA26Tfr1R654A/Tfr1R654A mice was
accompanied by decreased hepcidin mRNA expression. The
decrease in hepcidin expression in ROSA26Tfr1R654A/Tfr1R654A
mice was not as severe as observed in Hfe/ animals, perhaps
because not all Hfe is constitutively bound to Tfr1. Nonetheless,
taken together, our data reveal that mice constitutively express-
ing a mutant Tfr1 molecule that does not bind Tf but interactsCell Metabolism 7, 205–214, March 2008 ª2008 Elsevier Inc. 207
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Hfe Regulates Hepcidin ExpressionFigure 2. Phenotypic Analysis of ROSA26Tfr1R654A/Tfr1R654A Mice
(A) Top lane: Tfr1 protein expression was analyzed in 8-week-old wild-type (WT), ROSA26Tfr1R654A/+, ROSA26Tfr1R654A/Tfr1R654A, Hfe/, and Hfe/
ROSA26Tfr1R654A/+ animals by western blot. Bottom lane: equivalent loading of liver lysate was confirmed by immunoblot analysis using an anti-b-actin antibody.
(B–D) Box plots depicting the measurement of serum Tf saturation (%) (B), nonheme liver iron (mg/g wet weight) (C), and nonheme heart iron (mg/g wet weight) (D). WT
(n = 18, a),ROSA26Tfr1R654A/Tfr1R654A (n = 15, b),Hfe/ (n = 17, c), andHfe/ROSA26Tfr1R654A/+ (n = 13, d) are depicted in pink, yellow, white, and blue, respectively.
The middle bar of the box represents the median, while the top of the box is the 75th percentile and the bottom of box is the 25th percentile. The top and bottom
whiskers depict the 90th and 10th percentile of the data, respectively. Data outside of the 10th and 90th percentiles are represented as circles. p values were cal-
culated with Microsoft Excel (Student’s t test). p < 0.001 in (B) for a versus b, c, or d; p < 0.005 in (C) for all comparisonsexceptc versusd (p = not significant); p < 0.001
in (D) for b versus a, c, or d (p = not significant for all others).
(E) Total mRNA was harvested fromROSA26Tfr1R654A/Tfr1R654A livers (n = 5; results are expressed as mean ± SEM), and hepcidin mRNA was assessed by quantitative
real-time PCR. Mean mRNA expression for WT mice was set as 1, and all other data were expressed in relation to this. *p < 0.03 versus WT mRNA expression.
(F–H) DAB-enhanced Perls stain for iron in WT (F), ROSA26Tfr1R654A/Tfr1R654A (G), and Hfe/ (H) liver sections. Brown staining demonstrates iron accumulation
in cells.normally with Hfe have a phenotype similar, but not identical, to
that of Hfe/ mice. These data support the hypothesis that Hfe
functions to induce hepcidin expression when it is not interacting
with Tfr1.
Analysis of Mice Carrying an L622A Mutation
within the Endogenous Tfr1 Locus
To examine the role of the Hfe/Tfr1 complex from a different per-
spective, we introduced an L622A mutation into the endogenous
Tfr1 gene. This substitution should prevent interaction of Hfe with
Tfr1 but should not significantly interfere with the Tf cycle in vivo
(Figure 1D). We found that Tfr1L622A/L622A mice had a slight yet
significant decrease in serum Tf saturation, though liver non-
heme iron content was normal (Figures 3A and 3B). There was
no evidence of excess iron deposition on examination of liver
sections (data not shown). Complete blood counts revealed
mild hypochromic microcytic anemia in the L622A mutant ani-
mals, indicative of iron-deficient erythropoiesis (Table 1).208 Cell Metabolism 7, 205–214, March 2008 ª2008 Elsevier Inc.To determine whether decreased serum iron and iron-defi-
cient erythropoiesis might be the consequences of increased
hepcidin production, as observed previously in hepcidin trans-
genic mice (Nicolas et al., 2002; Roy et al., 2007), we examined
liver hepcidin mRNA expression by quantitative PCR. In normal
animals, hepcidin mRNA expression increases in response to
iron loading (Pigeon et al., 2001). This response is blunted in
Hfe/ mice (Bridle et al., 2003; Muckenthaler et al., 2003;
Nicolas et al., 2003) and ROSA26Tfr1R654A/Tfr1R654A mice
(Figure 2E). In contrast, Tfr1L622A/L622A mice, which should
have no interaction of Hfe with Tfr1, had an almost 2-fold in-
crease in basal levels of liver hepcidin mRNA (Figure 3C). This in-
crease in hepcidin likely explains the decreased Tf saturation
and the iron-deficient erythropoiesis in these animals.
Analysis of Hfe Transgenic Mice
Thus far, our data were most consistent with the interpretation that
Hfe signals to induce hepcidin expression when it is not in
Cell Metabolism
Hfe Regulates Hepcidin ExpressionFigure 3. Phenotypic Analysis of Tfr1L622A/L622A Mice
(A and B) Box plots depicting the measurement of serum Tf saturation (%) (A) and nonheme liver iron (mg/g wet weight) (B) as in Figure 2. WT (n = 21) and
Tfr1L622A/L622A (n = 16) are depicted in pink and yellow, respectively. p < 0.02 in (A); p = not significant in (B).
(C) Liver hepcidin mRNA was analyzed and graphed as in Figure 2. *p < 0.03 versus WT mRNA expression.
Results are expressed as mean ± SEM.complex with Tfr1. Accumulating evidence suggests that Hfe acts
in the hepatocyte itself, rather than in a different cell type. To fur-
ther test both of these ideas, we developed Hfe transgenic mice
by placingHfe cDNA under the control of the hepatocyte-specific
transthyretin (Ttr) promoter (Figures S2E and S2F). This promoter
mediates high-level, hepatocyte-specific expression at all devel-
opmental stages in a copy-number-independent fashion (Yan
et al., 1990). Mice expressing the Hfe transgene were bred with
Hfe/ mice of the same genetic background to produce animals
lacking expression of endogenous Hfe, with high levels of trans-
genic Hfe mRNA produced only in the liver (Figure S3).
We compared mice carrying the transgene on anHfe/ back-
ground to both Hfe/ and wild-type animals. We found that the
transgene not only corrected the increased Tf saturation and
liver iron overload in Hfe/ mice but also caused iron deficiency
(Figures 4A and 4B). Hfe/ mice carrying the transgene had
lower Tf saturation and less hepatic nonheme iron than wild-
type controls. Furthermore, while Hfe/ animals displayed
greatly increased liver iron loading in periportal regions of the
liver as expected, Hfe/ animals expressing the transgene
had less stainable hepatic iron than wild-type animals (Figures
4D–4F). Accordingly, complete blood counts revealed that the
transgenic Hfe/ animals had hypochromic microcytic anemia
attributable to severe iron deficiency (Table 2). Analysis of liver
tissue revealed that Hfe/ mice carrying the transgene not
only expressed more hepcidin mRNA than Hfe/ mice but
also expressed more hepcidin than wild-type controls
(Figure 4C). Elevated hepcidin expression, inappropriate for
body iron stores, likely accounts for the iron-deficient and ane-
mic phenotype of the transgenic Hfe/ mice. Because Hfe is
expressed at high levels in the transgenic mice, these results fur-
ther support the conclusion that hepatocytic Hfe, unbound to
Tfr1, signals to induce hepcidin expression.Recently, Enns and colleagues reported that both HFE and
iron-loaded TF stabilize TFR2 protein in human hepatoma cells
(Chen et al., 2007; Johnson et al., 2007). We observed that the
amount of hepatic Tfr2 protein was increased in Hfe/ animals
but markedly decreased after expression of the Hfe transgene in
Hfe/ mice (Figure 4G). These observations are consistent with
the interpretation that Tfr2 is stabilized by increased Tf saturation
in Hfe/ mice and that the stabilization does not occur when Tf
saturation is lowered by expression of the Hfe transgene. Thus,
while Hfe may play some role in the stabilization of Tfr2, under
these circumstances Tf saturation appears to be the dominant
factor.
DISCUSSION
Most patients with hemochromatosis are homozygous for a mis-
sense mutation altering the gene encoding HFE. HFE forms
a protein-protein complex with TFR1, a protein important for cel-
lular iron uptake. Although these facts have been known for more
than a decade, the molecular function of HFE is not yet under-
stood. Recent studies indicate that HFE is involved in modulating
the expression of hepcidin, but how it does so is not known. We
set out to explore the role of the murine Hfe/Tfr1 complex in vivo
by deliberately altering the stoichiometry of its component pro-
teins. We developed one mouse model in which Hfe should con-
stitutively interact with Tfr1 and two other models in which most
or all Hfe should be free of Tfr1. Our results suggest that Tfr1
serves to sequester Hfe and that Hfe acts to induce hepcidin
expression when it is independent of Tfr1 in hepatocytes.
We had unintentionally examined the effects of changing the
stoichiometry of the Hfe/Tfr1 interaction in earlier experiments
studying Tfr1+/ mice (Levy et al., 1999a, 2000). We observed
that animals lacking one endogenous Tfr1 allele have decreasedTable 1. Hematologic Features of Tfr1L622A/L622A Mice
Genotype n Hgb (g/dl) Hct (%) MCV (fl) MCH (pg) RDW (%) Retic (%) CHr (pg)
WT 23 15.3 ± 0.2 50.9 ± 0.5 56.5 ± 0.3 17.0 ± 0.1 12.4 ± 0.1 5.1 ± 0.4 16.4 ± 0.1
Tfr1L622A/L622A 15 14.5 ± 0.2* 45.8 ± 0.4* 50.3 ± 0.3* 15.9 ± 0.1* 13.8 ± 0.1* 5.2 ± 0.3y 16.4 ± 0.1y
The red blood cell parameters hemoglobin (Hgb), hematocrit (Hct), mean cell volume (MCV), mean cell hemoglobin (MCH), red cell distribution width
(RDW), reticulocyte count (Retic), and reticulocyte mean cell hemoglobin (CHr) were measured in 8-week-old female wild-type (WT) and Tfr1L622A/L622A
mice. Data are presented as mean ± SEM. p values were calculated by Student’s t test using Microsoft Excel. *p < 0.001 versus WT; yp = not significant
versus WT.Cell Metabolism 7, 205–214, March 2008 ª2008 Elsevier Inc. 209
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Hfe Regulates Hepcidin ExpressionFigure 4. Phenotypic Analysis of Mice Expressing a Hepatocyte-Specific Hfe Transgene
(A and B) Box plots depicting the measurement of transferrin saturation (%) (A) and nonheme liver iron (mg/g wet weight) (B) as in Figure 2. WT (n = 14, a), Hfe/
(n = 15, b), and Hfe/ Hfe transgenic (tg) (n = 7, c), are depicted in pink, yellow, and white, respectively. p < 0.001 in (A) and (B) for all comparisons between
groups. Results are expressed as mean ± SEM.
(C) Liver hepcidin mRNA was analyzed and graphically represented as in Figure 2. #p < 0.05, *p = 0.03 versus WT mRNA expression. Results are expressed as
mean ± SEM.
(D–F) DAB-enhanced Perls stain for iron in WT (D), Hfe/ (E), and Hfe/ Hfe tg (F) liver sections.
(G) Top lane: Tfr2 protein expression was analyzed in WT, Hfe/, and Hfe/ Hfe tg liver samples by western blot. Bottom lane: equivalent loading of liver lysate
was confirmed by immunoblot analysis using an anti-b-actin antibody.hepatic iron stores and evidence of iron-restricted erythropoie-
sis. While there are several possible reasons for this observation,
it could be explained by an increase in Hfe that is not associated
with Tfr1 and a consequent increase in hepcidin production. Ac-
cordingly, we later showed that Tfr1+/ mice produce increased
hepcidin mRNA (C.N. Roy and N.C.A., unpublished data). A
model in which Tfr1 normally sequesters Hfe reconciles these
findings. We suggest that haploinsufficiency for Tfr1 results in
more unbound Hfe, signaling for an increase of hepcidin expres-
sion.
Although the mutant mouse strains described in this report
have been instructive, there are several observations that we
do not fully understand. First, mice expressing the Tfr1 R654A210 Cell Metabolism 7, 205–214, March 2008 ª2008 Elsevier Inc.transgene do not accumulate as much iron as Hfe/ mice.
This may be because there is still some Hfe that is not interacting
with the mutant Tfr1. Additionally, it is possible that the mutant
Tfr1 protein forms heterodimers with wild-type Tfr1, impairing
normal Tf uptake. If this occurs, however, our data indicate
that it is clearly not an issue in the erythron, where we previously
showed the Tf cycle to be most important (Levy et al., 1999a).
We also observed that animals carrying the R654A transgene
on an Hfe/ background have a milder phenotype than Hfe/
mice, even though no Hfe is produced. Along the same lines,
we previously observed that Hfe/ mice lacking one Tfr1 allele
(Hfe/ Tfr1+/) have more iron overload than Hfe/ mice with
both Tfr1 alleles intact (Levy et al., 2000). These results suggestTable 2. Hematologic Features of Hfe/ Hfe Transgenic Animals
Genotype n Hgb (g/dl) Hct (%) MCV (fl) MCH (pg) RDW (%) Retic (%) CHr (pg)
WT 12 14.7 ± 0.1 46.8 ± 0.4 49.6 ± 0.3 15.6 ± 0.1 13.4 ± 0.2 3.6 ± 0.2 16.3 ± 0.1
Hfe/ 14 15.6 ± 0.2* 50.6 ± 0.8* 52.6 ± 0.6* 16.3 ± 0.1* 13.1 ± 0.2y 3.6 ± 0.2y 16.2 ± 0.7y
Hfe/ Hfe tg 6 12 ± 0.3*x 39.9 ± 0.8*x 38.2 ± 0.6*x 11.5 ± 0.1*x 22.2 ± 0.7*x 4.5 ± 0.4yz 12.8 ± 0.2*x
The red blood cell parameters hemoglobin (Hgb), hematocrit (Hct), mean cell volume (MCV), mean cell hemoglobin (MCH), red cell distribution width
(RDW), reticulocyte count (Retic), and reticulocyte mean cell hemoglobin (CHr) were measured in 8-week-old female wild-type (WT),Hfe/, andHfe/
Hfe transgenic (tg) mice. Data are presented as mean ± SEM. p values were calculated by Student’s t test using Microsoft Excel. *p < 0.001 versus WT;
yp = not significant versus WT. xp < 0.001 versus Hfe/; zp = not significant versus Hfe/.
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Iron Sensing
Hfe-Tfr1 complexes on the surface of hepatocytes
sense the saturation of iron-bound transferrin in
the serum. At low transferrin saturations, Hfe is se-
questered by Tfr1 (left). As serum iron saturation
increases, Hfe is dislodged from its overlapping
binding site on Tfr1 by Fe-Tf (right). Hfe is then
free to interact with Tfr2 and signal in some man-
ner for the upregulation of hepcidin. Increased
levels of circulating hepcidin lead to a reduction
in both intestinal iron absorption and macrophage
iron release. If either Hfe or Tfr2 is mutated or ab-
sent, the complex is unable to sense increased se-
rum Tf saturation, and dysregulation of iron ho-
meostasis occurs.that Tfr1 may interact with another protein important for regula-
tion of iron homeostasis. It is conceivable that mutations in Tfr1
have some impact on the function of Tfr2, even though they do
not appear to heterodimerize to any great extent (Vogt et al.,
2003). Alternatively, there may be another protein that is structur-
ally similar to Hfe, which interacts with Tfr1 in a comparable fash-
ion. Accordingly, there is some evidence that classical major his-
tocompatibility class I molecules may be involved in iron
homeostasis (Cardoso et al., 2002).
Atransferrinemia is a distinct iron overload disorder resulting
from mutations in the gene encoding serum TF (Beutler et al.,
2000; Trenor et al., 2000). Affected patients and mice suffer se-
vere microcytic anemia due to iron-restricted erythropoiesis but
manifest iron overload in nonhematopoietic tissues. We propose
that Tfr1 normally acts to sequester Hfe and that increasing Fe-Tf
causes a competition with Hfe for Tfr1 binding. In Tfhpx/hpx mice,
a lack of Tf prevents this competition. As a result, a dispropor-
tionately large amount of Hfe may remain constitutively bound
to Tfr1 and be unable to signal for the upregulation of hepcidin.
Our hypothesis correctly predicts that Tfhpx/hpx animals should
hyperaccumulate iron even though they are severely anemic.
This situation is similar to the mouse model expressing the Tfr1
R654A transgene from the ROSA26 locus, which should form
the Hfe-Tfr1 complex constitutively.
Mutations in both HFE and TFR2 are known to cause hemo-
chromatosis. Hfe and Tfr2 interact in cultured cells, and Tfr2
competes with Tfr1 for Hfe binding (Goswami and Andrews,
2006). It is reasonable to expect that, under normal homeostatic
conditions, Hfe is partitioned between Tfr1, Tfr2, and possibly
other proteins. As Tf saturation increases, Tf likely displaces
Hfe from Tfr1. Furthermore, increased Tf saturation results in sta-
bilization of Tfr2 protein (Johnson and Enns, 2004; Robb and
Wessling-Resnick, 2004) and degradation of Tfr1 mRNA (Eisen-
stein, 2000). All of these effects should shift Hfe away from inter-
action with Tfr1 and toward interaction with Tfr2, as depicted in
our working model (Figure 5). Conversely, low-iron conditions
should favor interaction between Hfe and Tfr1. As we show in
our Tfr1 mutant mouse models, as Hfe is uncoupled from Tfr1
binding, hepcidin levels are upregulated. We propose that an
Hfe/Tfr2 complex helps to propagate a signaling cascade result-
ing in the upregulation of hepcidin and, consequently, decreased
dietary iron uptake and decreased macrophage iron release.
Mutations in either HFE or TFR2 would impair this putative sig-naling complex, causing a failure to properly upregulate hepci-
din, resulting in clinical hemochromatosis.
EXPERIMENTAL PROCEDURES
Surface Plasmon Resonance Analysis of Mutant Tfr1
The soluble mouse Tfr1 ectodomain was cloned and produced analogously to
the human TFR1 described previously (Lebron et al., 1999; West et al., 2001).
After subcloning Tfr1 into the pACGP67A baculovirus expression vector,
L622A and R654A mutations were introduced using the QuikChange Site-
Directed Mutagenesis Kit (Stratagene). Baculovirus supernatants containing
the secreted receptor were used in a surface plasmon resonance assay as de-
scribed previously (Giannetti and Bjorkman, 2004; Giannetti et al., 2003).
Mouse Hfe was produced as described previously (Lebron et al., 1999) by co-
expression of the mouse Hfe heavy chain with human b2-microglobulin in CHO
cells. Protein was purified from concentrated CHO cell supernatants using
a BBM.1 (anti-human b2-microglobulin) column and eluted with 50 mM dieth-
ylamine (pH 11.5) into tubes containing 1 M Tris (pH 7.4) to preserve purity.
Eluted protein was further purified on an S-200 sizing column to eliminate small
quantities of aggregate. Mouse apo-Tf was purchased from Sigma, loaded
with iron as described previously (Giannetti et al., 2003), and purified on an
S-200 sizing column. All biosensor experiments were performed as described
previously (Giannetti and Bjorkman, 2004; Giannetti et al., 2003), with the ex-
ception that data reduction, double referencing, and analysis were performed
with the Scrubber II software package (BioLogic Software). A simple 1:1 bind-
ing model could describe the binding interactions with the mouse proteins,
rather than the more complex bivalent ligand model used for the human
system.
Oligonucleotide Primers
Oligonucleotide primers are listed in Table S2.
Iron Uptake by Mutant Tfr1 Molecules
We mutated the vector pBS+-Tfr1, containing the complete mouse Tfr1 cDNA,
using the QuikChange kit and primers PS-9 and PS-10 to create the L622A mu-
tation. Primers PS-11 and PS-12 were used to create the R654A mutation. The
wild-type, L622A, and R654A Tfr1 cDNA-containing vectors were amplified
with primers PS-48 and PS-49 to insert a BamHI site immediately before the
translational start codon and an XhoI site in place of the endogenous stop co-
don. These PCR products were purified with a QIAGEN PCR purification kit,
digested with BamHI and XhoI, and ligated into pcDNA3.1 V5/His (Invitrogen).
Sequence analysis demonstrated that the Myc epitope tag in each vector was
out of frame. In order to place the epitope tag of each expression vector into
frame, all three constructs were mutagenized with the QuikChange kit using
primers PS-62 and PS-63. Final sequence analysis showed that the vectors
contained the correct sequence. The vectors containing wild-type, L622A,
and R654A forms of the Tfr1 cDNA were named pPJS040, 041, and 042,
respectively. Stable clones were obtained in TRVb cells, which contain no en-
dogenous Tfr1 (McGraw et al., 1987), by electroporation and selection withCell Metabolism 7, 205–214, March 2008 ª2008 Elsevier Inc. 211
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mented with 5% fetal bovine serum, 1% penicillin/streptomycin, 1% L-gluta-
mine, and 2 g/l dextrose and maintained under selection in 400 mg/ml G418.
55Fe-Tf preparation and uptake procedures were modified from a previously
described protocol (Roy et al., 1999). 55FeCl3 (Amersham Biosciences) was
complexed to nitrilotriacetic acid (NTA) by adding 55FeCl3 to 1 ml 0.1 M NTA
solution (1:50 ratio Fe:NTA). Then, 4-fold excess 55Fe-NTA was incubated
with murine apo-Tf for 1.5 hr in carbonate buffer (10 mM NaHCO3, 0.25 M
Tris-HCl). 55Fe-Tf was separated from free 55Fe on a 3 ml G-50 Sephadex col-
umn (Sigma). The resulting Tf was almost completely saturated with iron.
To determine the rate of Fe-Tf uptake into the stable Tfr1-TRVb cell lines,
cells were plated below confluence in six-well dishes. Plates were washed
two times with serum-free medium (Ham’s F12, 20 mM HEPES) and preincu-
bated at 37C/5% CO2 for 15 min. Plates were removed, and the medium was
aspirated. One milliliter of specific medium (100 nM 55Fe-Tf, 2 mg/ml ovalbu-
min) was added to four wells for each time point (0, 45, 90, 135, and 225 min).
Nonspecific ligand (same as specific medium with the addition of 10-fold ex-
cess cold Fe-Tf) was added to two wells for each time point, and all samples
were placed at 37C/5% CO2. Cells were placed on ice at a given time point,
and the medium was aspirated. Externally bound Tf was stripped by incuba-
tion with 2.0 ml of acidic buffer (0.5 N acetic acid, 0.5 M NaCl, 1 mM FeCl3)
for 3 min. Cells were washed three times with final wash solution (150 mM
NaCl, 20 mM HEPES [pH 7.4], 1 mM CaCl2, 5 mM KCl, 1 mM MgCl2) on ice.
Cells were solubilized in 1.0 ml 0.1% Triton X-100, 0.1 N NaOH and counted
in a gamma counter.
Generation of ROSA26Tfr1R654A/Tfr1R654A Mice
To generate the transgenic ROSA26 Tfr1 R654A targeting vector, mouse Tfr1
cDNA contained within plasmid pBS+-TFR1 was mutagenized with the Quik-
Change kit as described earlier. The insert was liberated with SacI and NotI,
gel purified, and ligated into plasmid pBigT (kind gift of F. Costantini, Columbia
University). The resultant plasmid was digested with PacI and AscI, and re-
cessed 30 ends were filled with DNA polymerase I, large (Klenow) fragment
(New England Biolabs). This fragment was ligated into a similarly filled XbaI
site in pROSA26-1 (kind gift of P. Soriano, Fred Hutchinson Cancer Research
Center). The final vector was analyzed by DNA sequencing and named
pPJS022. This plasmid was linearized with KpnI, gel purified away from vector
sequence using the Geneclean kit (Bio 101), and electroporated into J1 embry-
onic stem cells (129 background). Cells were selected for resistance to G418
and ganciclovir. Correctly targeted clones were identified by both Southern
blotting and PCR analysis and were karyotyped to confirm a correct comple-
ment of mouse chromosomes. Blastocyst injections were performed at the
Children’s Hospital Boston Mental Retardation Research Center Gene Manip-
ulation Facility. Founders were identified by Southern blot analysis and/or PCR
genotyping of tail DNA, and residual vector sequences were removed in vivo
by breeding to E2A-Cre transgenic mice.
Generation of Tfr1L622A/L622A Mice
To generate the L622A knockin Tfr1 allele, two 4 kb arms of the murine Tfr1
gene were amplified from a mouse 129Sv/J bacterial artificial chromosome li-
brary using primers PS-1 and PS-2 for the 50 fragment and primers PS-3 and
PS-24 for the 30 fragment. Each PCR product was subcloned into the pCR2.1-
TOPO cloning vector (Clontech). The L622A mutation was inserted into exon
17 of the 50 fragment using the QuikChange kit and primers described earlier.
The 50 fragment-containing vector was digested with ClaI, 30 overhangs were
filled with Klenow enzyme, and the product was then further digested with
XhoI. This fragment was gel purified with a Geneclean Spin kit and then subcl-
oned into vector pNTKBLP between the HpaI and XhoI sites. pNTKBLP is the
pKO Scrambler NTKV-1907 (Stratagene) backbone with the neomycin cas-
sette excised with AscI. A floxed neomycin cassette was released from its vec-
tor backbone with NotI, overhangs were filled with Klenow enzyme, and the re-
sulting fragment was cloned into pKO Scrambler NTKV-1907 to produce
pNTKBLP. The 30 arm of the Tfr1 sequence was liberated with SacII and
XmaI digestion, gel purified, and ligated into the pNTKBLP vector already con-
taining the 50 region. The final vector (pPJS015) was sequenced to confirm the
correct DNA sequence of each exon and exon/intron boundary. This construct
was introduced into J1 ES cells by electroporation after linearization with PvuI,
and cells were selected for resistance to both G418 and ganciclovir. Correctly212 Cell Metabolism 7, 205–214, March 2008 ª2008 Elsevier Inc.targeted mutants were identified by Southern blot analysis. The targeting effi-
ciency was approximately 7%. Five positive clones were karyotyped, and two
were selected for injection. ES cells containing the correctly targeted Tfr1 allele
were injected into C57BL/6J blastocysts at the Children’s Hospital Boston
Center for Molecular Developmental Hematopoiesis. Founders were identified
by Southern blot and/or PCR analysis. The neomycin selection cassette was
removed by Cre-loxP recombination after breeding to E2A-Cre transgenic
mice. All mice homozygous for the L622A mutated allele were generated
from a cross of Tfr1L622A/L622A parents.
Generation of Transgenic Mice Expressing Hfe under
Control of the Ttr Promoter
The complete 1.1 kb mouse Hfe cDNA was amplified using the primers HFEt-
gREV and HFEtgFOR from a cDNA template contained in pcDNA3.1 and
subcloned into pCR2.1-TOPO. This fragment was liberated with SpeI and
EcoRV. The 30 overhangs were filled with Klenow enzyme, and the resulting se-
quence ligated into the blunted StuI site in the pTTR1exV3 vector (kind gift of
T. Van Dyke, University of North Carolina). Correct orientation and sequence
were confirmed by sequencing analysis. The excised HindIII fragment was pu-
rified from the vector by electroelution and microinjected into C57BL/6 oocyte
pronuclei at the Children’s Hospital Boston Center for Molecular Developmen-
tal Hematopoiesis. These mice were bred with anHfe/ strain of the same ge-
netic background to generate Hfe/ animals carrying the integrated Ttr-Hfe
transgene.
Animal Care and Analysis
All mice were born and housed in the barrier facility at Children’s Hospital Bos-
ton according to approved protocols. Animals were maintained on the Prolab
RMH 300 diet (PMI Nutrition), with food and water provided ad libitum. Due to
inherent differences in iron metabolism between male and female animals,
only females were employed for analysis. All animals were euthanized at
8 weeks of age for analysis.
Southern Blot and PCR Genotyping
The Puregene DNA isolation kit (Gentra Systems) was used to prepare geno-
mic DNA from tail snips. For Southern blot analysis, DNA (10 mg) was digested
overnight, fractionated on a 0.7% agarose gel, and then transferred to Hybond
N+ membrane (Amersham). Blots were probed with a 32P-dCTP-labeled prod-
uct. Genomic DNA from mice containing the L622A mutation was digested
with BamHI and probed with a labeled PCR product amplified using primers
PS-36 and PS-37 to genotype the 50 end of the insertion. The 30 end of the
gene was probed with a labeled PCR product amplified using primers PS-38
and PS-39. These mice were also PCR genotyped using forward primer PS-
71a and reverse primer L622AF, giving either a 292 bp band for the targeted
allele or a 269 bp band for the wild-type allele. Genomic DNA from ROSA26
Tfr1 R654A mice was digested with EcoRV and probed with a PCR product
amplified with primers ROSA A and ROSA B. Mice were also PCR genotyped
using primers PS-64a and PS-65. The same forward primer and the reverse
primer PS-102 produce a 614 bp band for the mutant allele. Transgenic
Ttr-Hfe mice were PCR genotyped with primers PS-133 and PS-134, yielding
a 450 bp band.
Tissue Iron Staining
Tissue samples of liver and spleen were fixed in 10% buffered formalin for 24 hr
and then embedded in paraffin. Deparaffinized tissue sections were stained
with DAB-enhanced Perls iron stain by the Children’s Hospital Boston Pathol-
ogy Laboratory.
Blood and Tissue Iron Analysis
Whole blood for complete blood counts was collected retro-orbitally into
EDTA-coated microtainer tubes (Becton Dickinson) from animals anesthetized
with Avertin (Sigma). Samples were analyzed on an Avida 120 analyzer (Bayer)
by the Children’s Hospital Boston Clinical Core Laboratories. Whole blood for
serum iron and transferrin saturation determination was collected by retro-
orbital bleeding in serum separator tubes (Becton Dickinson), and serum
was prepared according to the manufacturer’s instructions. Serum iron values
were determined with a serum iron/UIBC kit (Thermo DMA) according to the
manufacturer’s instructions. Liver and spleen tissues were collected and
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(Levy et al., 1999a; Torrance and Bothwell, 1980).
RNA Extraction, RT-PCR, and Quantitative PCR
Total liver RNA was isolated from flash-frozen tissue using RNA STAT-60
(Leedo Medical Laboratories). Total RNA was treated with DNase I (Roche)
to remove contaminating genomic DNA per the manufacturer’s instructions.
cDNA was synthesized from the resulting RNA using the iScript cDNA Synthe-
sis Kit (Bio-Rad) according to the manufacturer’s protocol. Real-time quantifi-
cation of hepcidin and b-actin mRNA transcript levels was performed with iQ
SYBR Green Supermix (Bio-Rad) in a 20 ml reaction in an iCycler instrument
(Bio-Rad) according to the manufacturer’s instructions. Hepcidin mRNA was
amplified using primers Hamp1 F and Hamp1 R. Control b-actin mRNA was
amplified using primers b-actin F and b-actin R as described previously (Nem-
eth et al., 2004a). Amplification conditions were as follows: 95C for 3 min and
then 95C for 10 s, 60C for 45 s for 45 cycles. Hepcidin transcript abundance
was calculated in triplicate relative to the expression of the stable housekeep-
ing gene b-actin and presented as a ratio to the wild-type control in each ex-
periment. The average relative expression of hepcidin in wild-type 129SvEv/
Tac animals was assigned an arbitrary value of 1 in each experiment.
Immunoblot Analysis
Liver tissue was manually lysed in modified RIPA buffer (50 mM Tris [pH 7.5],
150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS). Cultured
cells were washed with cold PBS, scraped into PBS, pelleted gently, and lysed
in IP lysis buffer (150 mM NaCl, 50 mM Tris-HCl [pH 8.0], 1% Triton X-100). Cell
debris was removed by centrifugation. Total tissue protein (75 or 150 mg) or cell
lysate (40 mg) was diluted in 23 Laemmli buffer (0.2 M DTT final), boiled, and
subjected to electrophoresis through 8% or 10% polyacrylamide gels. The
proteins were transferred onto nitrocellulose membranes, and immunoblot
analysis was performed using mouse anti-hTFR1 (1:1000, Zymed), rabbit
anti-mouse Tfr2 (1:1000, Alpha Diagnostic International), or rabbit anti-b-actin
(1:1000, Cell Signaling). Blots were incubated with either anti-mouse or anti-
rabbit secondary antibody conjugated to horseradish peroxidase (1:5000)
and then subjected to chemiluminescence (Amersham ECL) per the manufac-
turer’s directions.
SUPPLEMENTAL DATA
Supplemental Data include two tables and three figures and can be found with
this article online at http://www.cellmetabolism.org/cgi/content/full/7/3/205/
DC1/.
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